<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-876
Date of Submission: 2025-02-10

This report was submitted by a Patient from Moss Inc Medical Center concerning patient ANON-PX-3359. The subject is an adult female with a significant medical history including asthma, coronary artery disease, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Topical route at a dosage of 83mg, initiated on 2025-01-30 for Pain and inflammation and discontinued on 2025-02-07; Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 481mg, initiated on 2025-01-30 for Thromboembolism prevention and discontinued on 2025-02-07.

On approximately 2025-02-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Stevens-Johnson syndrome, Diarrhea. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Woman instead top prove material history.</data>
report_id: ADR-2025-876
report_date: '2025-02-10'
patient_details:
  patient_id: ANON-PX-3359
  gender: Female
  relevant_history:
  - asthma
  - coronary artery disease
  - seasonal allergies
suspected_drugs:
- drug_name: Ibuprofen
  dosage: 83mg
  route_of_administration: Topical
  start_date: '2025-01-30'
  indication_for_use: Pain and inflammation
  drug_class: NSAID
  end_date: '2025-02-07'
- drug_name: Warfarin
  dosage: 481mg
  route_of_administration: Intravenous
  start_date: '2025-01-30'
  indication_for_use: Thromboembolism prevention
  drug_class: Anticoagulant
  end_date: '2025-02-07'
adverse_reactions:
- symptom_name: Pruritus
  onset_date: '2025-02-07'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-02-07'
  severity: Severe
  outcome: Fatal
  intervention_required: true
- symptom_name: Diarrhea
  onset_date: '2025-02-07'
  severity: Severe
  outcome: Fatal
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Negative dechallenge
reporting_facility: Moss Inc Medical Center
reporter_type: Patient
notes: Woman instead top prove material history.
